Dimerization inhibitors of HIV-1 protease
- PMID: 12437124
- DOI: 10.1515/BC.2002.150
Dimerization inhibitors of HIV-1 protease
Abstract
By targeting the highly conserved antiparallel beta-sheet formed by the interdigitation of the N- and C-terminal strands of each monomer, dimerization inhibitors of HIV-1 protease may be useful to overcome the drug resistance observed with current active-site directed antiproteases. Sequestration of the monomer by the inhibitor (or disruption of the dimer interface) prevents the correct assembly of the inactive monomers to active enzyme. Strategies for the design of drugs targeting the dimer interface are described. Various dimerization inhibitors are reported including N- and C-terminal mimetics, lipopeptides and cross-linked interface peptides.
Similar articles
-
An alternative strategy for inhibiting multidrug-resistant mutants of the dimeric HIV-1 protease by targeting the subunit interface.Biochem Soc Trans. 2007 Jun;35(Pt 3):551-4. doi: 10.1042/BST0350551. Biochem Soc Trans. 2007. PMID: 17511649
-
Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.Biopolymers. 2002;66(2):126-33. doi: 10.1002/bip.10232. Biopolymers. 2002. PMID: 12325162 Review.
-
Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling.Biopolymers. 2007;88(2):164-73. doi: 10.1002/bip.20685. Biopolymers. 2007. PMID: 17236209
-
Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases.Biochemistry. 2009 Jan 20;48(2):379-87. doi: 10.1021/bi801422u. Biochemistry. 2009. PMID: 19105629
-
HIV-1 protease folding and the design of drugs which do not create resistance.Curr Opin Struct Biol. 2008 Feb;18(1):60-6. doi: 10.1016/j.sbi.2007.10.004. Epub 2007 Dec 21. Curr Opin Struct Biol. 2008. PMID: 18160276 Review.
Cited by
-
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors.Acta Pharm Sin B. 2024 Jan;14(1):87-109. doi: 10.1016/j.apsb.2023.08.004. Epub 2023 Aug 9. Acta Pharm Sin B. 2024. PMID: 38239241 Free PMC article. Review.
-
Unexpected Single-Ligand Occupancy and Negative Cooperativity in the SARS-CoV-2 Main Protease.J Chem Inf Model. 2024 Feb 12;64(3):892-904. doi: 10.1021/acs.jcim.3c01497. Epub 2023 Dec 5. J Chem Inf Model. 2024. PMID: 38051605 Free PMC article.
-
Interfacial Water Many-Body Effects Drive Structural Dynamics and Allosteric Interactions in SARS-CoV-2 Main Protease Dimerization Interface.J Phys Chem Lett. 2021 Jul 8;12(26):6218-6226. doi: 10.1021/acs.jpclett.1c01460. Epub 2021 Jul 1. J Phys Chem Lett. 2021. PMID: 34196568 Free PMC article.
-
The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design.BMC Microbiol. 2011 May 25;11:116. doi: 10.1186/1471-2180-11-116. BMC Microbiol. 2011. PMID: 21612658 Free PMC article.
-
Insight into the self-association of key enzymes from pathogenic species.Eur Biophys J. 2005 Jul;34(5):469-76. doi: 10.1007/s00249-005-0491-y. Epub 2005 Jun 25. Eur Biophys J. 2005. PMID: 15981001
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources